We are live on ! Find out more
SVA

Sinovac Biotech, Ltd
SVA

Delisted

SVA was delisted on the 22nd of February, 2019.

Back to rankings

3 hedge funds and large institutions have $336M invested in Sinovac Biotech, Ltd in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0% more capital invested

Capital invested by funds: $336M → $336M ($0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

25% less funds holding

Funds holding: 4 → 3 (-1)

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.04%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
1
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
O
1
OrbiMed
New York
$334M – – –
NAH
2
Neumann Advisory (HK)
Hong Kong
$2.04M – – –

SVA Hedge Fund Activity: Q1 2025 in Review

3 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2025, worth a combined $336M — unchanged from a quarter earlier.

Fund positioning in SVA was balanced in Q1 2025: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.

  • 3 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2025, down from 4 in Q4 2024.
  • Funds reported $336M of Sinovac Biotech, Ltd stock for Q1 2025, unchanged quarter-over-quarter.
  • 1 fund opened new Sinovac Biotech, Ltd positions in Q1 2025 and 1 closed out, a net change of 0 holders.

Based on aggregated 13F filings for Q1 2025.